Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

61. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. (Full text)

Rivaroxaban for thromboprophylaxis in acutely ill medical patients. The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo.We randomly assigned patients 40 years of age or older who were (...) hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary efficacy outcomes were the composite of asymptomatic proximal or symptomatic venous thromboembolism up to day 10 (noninferiority test) and up to day 35 (superiority test). The principal safety outcome was the composite of major or clinically relevant

2013 NEJM PubMed

62. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) Overview | Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | Guidance | NICE Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Technology appraisal guidance [TA287] Published date: 26 June 2013 Share Save Guidance on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

63. Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. (Full text)

Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. 22977402 2012 09 18 2018 11 13 1481-4501 1 2 2010 CADTH technology overviews CADTH Technol Overv Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. e0111 Canadian Agency for Drugs and Technologies

2012 CADTH technology overviews PubMed

64. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of rivaroxaban versus enoxaparin for prevention of venous thromboembolism in patients who underwent major orthopaedic surgery such as total hip or total knee replacement

2012 NHS Economic Evaluation Database.

65. Rivaroxaban - Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism

Rivaroxaban - Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism Common Drug Review CDEC Meeting – July 18, 2012 Notice of CDEC Final Recommendation – August 16, 2012 Page 1 of 5 © 2012 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto – Bayer Inc.) New Indication: Deep Vein Thrombosis (Treatment) without Symptomatic Pulmonary Embolism Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be listed for the treatment of deep vein (...) thrombosis (DVT) in patients without symptomatic pulmonary embolism (PE), for a duration not to exceed six months. Reasons for the Recommendation: 1. In one large randomized controlled trial (RCT) of patients with acute symptomatic DVT without symptomatic PE (the EINSTEIN DVT trial), rivaroxaban was reported to be non- inferior to a regimen of enoxaparin plus a vitamin K antagonist (VKA) based on the incidence of recurrent DVT or PE. The majority of patients received treatment for six months or less

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

66. Rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. (PubMed)

Rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. 22910960 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. JC2-6 10.7326/0003-4819-157-4-201208210-02006 Witt Daniel M DM Kaiser Permanente Colorado, Aurora, Colorado, USA. eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819

2012 Annals of Internal Medicine

67. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons (Full text)

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic (...) for the use of new oral anticoagulants for prophylaxis against venous thromboembolism after total hip or knee replacement. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to April 2011. Clinical trial registries, relevant conference proceedings and websites of regulatory agencies were searched. The search strategy was available online. There were no language restrictions. Study selection Randomised controlled trials (RCTs) that compared rivaroxaban (10mg

2012 DARE. PubMed

68. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. (Full text)

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. To analyse clinical outcomes with new oral anticoagulants for prophylaxis against venous thromboembolism after total hip or knee replacement.Systematic review, meta-analysis, and indirect treatment comparisons.Medline and CENTRAL (up to April 2011), clinical trials registers, conference proceedings, and websites (...) of regulatory agencies.Randomised controlled trials of rivaroxaban, dabigatran, or apixaban compared with enoxaparin for prophylaxis against venous thromboembolism after total hip or knee replacement. Two investigators independently extracted data. Relative risks of symptomatic venous thromboembolism, clinically relevant bleeding, deaths, and a net clinical endpoint (composite of symptomatic venous thromboembolism, major bleeding, and death) were estimated using a random effect meta-analysis. RevMan and ITC

2012 BMJ PubMed

69. Rivaroxaban - Atrial fibrillation, stroke prevention

Rivaroxaban - Atrial fibrillation, stroke prevention Common Drug Review CDEC Meeting – March 21, 2012 Notice of CDEC Final Recommendation – April 19, 2012 Page 1 of 6 © 2012 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto – Bayer Inc.) New Indication: Atrial Fibrillation, Stroke Prevention Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be listed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (...) , in whom warfarin is indicated, and who meet all of the following criteria: • Are unable to achieve adequate anticoagulation with warfarin, and • Have a CHADS 2 score of = 2. Reasons for the Recommendation: 1. In one large double-blind randomized controlled trial (RCT) of patients with a CHADS 2 score of = 2 (ROCKET-AF), rivaroxaban was reported to be non-inferior, but not superior, to adjusted-dose warfarin, based on the incidence of stroke or systemic embolism. 2. At recommended doses of rivaroxaban

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

70. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

71. ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED DECEMBER 2012 – WWW.RXFILES.CA Page 1 of 4 ROCKET-AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation 1 Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS (...) 2 score 3.5), rivaroxaban 20mg po daily: ? Was non-inferior (i.e. no worse than) to warfarin for ? stroke or systemic embolism ? Had less hemorrhagic strokes, systemic embolism & bleeding (critical, fatal & intracranial) versus warfarin ? Had more drops in hemoglobin =20 g/L, tranfusions, gastrointestinal bleeding, epistaxis & hematuria versus warfarin ? At time of publication, rivaroxaban for AF is approximately $100/month; 15mg, 20mg tablets. ? A Fib, ? Warfarin + monitoring ~$35/month

2012 RxFiles

72. Randomised controlled trial: For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding (Full text)

Randomised controlled trial: For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content (...) are here For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding Article Text Therapeutics Randomised controlled trial For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding Matthew Sherwood , Jonathan P Piccini Statistics from Altmetric.com

2012 Evidence-Based Medicine (Requires free registration) PubMed

73. Rivaroxaban in patients with a recent acute coronary syndrome. (Full text)

Rivaroxaban in patients with a recent acute coronary syndrome. Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with a recent acute coronary syndrome to receive twice-daily doses (...) of either 2.5 mg or 5 mg of rivaroxaban or placebo for a mean of 13 months and up to 31 months. The primary efficacy end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke.Rivaroxaban significantly reduced the primary efficacy end point, as compared with placebo, with respective rates of 8.9% and 10.7% (hazard ratio in the rivaroxaban group, 0.84; 95% confidence interval [CI], 0.74 to 0.96; P=0.008), with significant improvement for both the twice-daily 2.5-mg

2012 NEJM PubMed

74. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Kansal AR, Sharma M (...) , Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of dabigatran versus rivaroxaban as anticoagulation therapies for prevention

2012 NHS Economic Evaluation Database.

75. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C CRD summary (...) All-cause deaths were equivalent for each treatment, but apixaban and dabigatran 110mg seemed to prevent more strokes, with least risk, for patients with non-valvular atrial fibrillation; dabigatran 150mg seemed better for patients at high risk of embolism. The review was generally poorly reported. The indirect comparisons and potential for confounding mean that the conclusions may not be reliable. Authors' objectives To compare the efficacy and safety of dabigatran, rivaroxaban, and apixaban

2012 DARE.

76. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. (Full text)

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism.In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism (...) with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.Rivaroxaban was noninferior to standard therapy (noninferiority margin, 2.0; P=0.003) for the primary efficacy outcome

2012 NEJM PubMed

77. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261) Overview | Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | Guidance | NICE Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Technology appraisal guidance [TA261] Published date: 25 July 2012 Share Guidance (...) on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed if there is new evidence that is likely to affect the recommendations. Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration

2012 National Institute for Health and Clinical Excellence - Technology Appraisals

78. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) Overview | Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | Guidance | NICE Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Technology appraisal guidance [TA256] Published date: 23 May 2012 Share Guidance on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non

2012 National Institute for Health and Clinical Excellence - Technology Appraisals

79. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

80. What role can dabigatran,rivaroxaban and apixaban play in the future?

What role can dabigatran,rivaroxaban and apixaban play in the future? Vol 19. DTB: Vol 19, No 3. May - July 2011 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 19, No 3. May - July 2011 DTB: Vol 19, No 3. May - July 2011 Content tools Share it What role can dabigatran, rivaroxaban and apixaban play in the future? Dabigatran, rivaroxaban and apixaban have shown to be non inferior to warfarin. However these drugs might

2011 Drug and Therapeutics Bulletin of Navarre (Spain)